Fusion Pharmaceuticals 2024 Corporate Presentation

Fusion Pharmaceuticals is a leader in radiopharmaceutical therapies developing targeted alpha therapies (TATs) for cancer treatment. The company's lead program, AcPSMA, is positioned as a first-to-market solution for post-lutetium mCRPC with FDA alignment on registration pathway, supported by strategic manufacturing capabilities and an AstraZeneca partnership.